WEZENLA

This brand name is authorized in Austria, Estonia, Spain, France, Lithuania

Active ingredients

The drug WEZENLA contains one active pharmaceutical ingredient (API):

1 Ustekinumab
UNII FU77B4U5Z0 - USTEKINUMAB

Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. Ustekinumab inhibits the bioactivity of human IL-12 and IL-23 by preventing p40 from binding to the IL-12R1 receptor protein expressed on the surface of immune cells. Abnormal regulation of IL 12 and IL 23 has been associated with immune mediated diseases, such as psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Read about Ustekinumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AC05 Ustekinumab L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 3083420, 3083431, 3083442, 3083453
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1241823001, 1241823002, 1241823003, 1241823004
Country: FR Base de données publique des médicaments Identifier(s): 60926807, 61082122, 61183445, 68430695
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1100126, 1100127, 1100128, 1100129

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈